Phase 3
Completed N=199
Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine
Schizophrenia · Schizoaffective Disorders
Source: ClinicalTrials.gov NCT00401973 ↗
Enrolled (actual)
199
Serious AEs
—
Results posted
Sep 2009
Primary outcomePrimary: Change From Baseline to Endpoint in Weight — 2.76; 2.40; 0.65 kilograms — p=0.065
Summary
The goal of this study is to answer the following questions:
* Whether treatment with amantadine, metformin or zonisamide can prevent or reverse the weight gain that is associated with olanzapine
* Whether taking amantadine, metformin or zonisamide can help patients decrease or eliminate some of the changes in body that occur with weight gain
* How weight gain associated with olanzapine can affect people
* Whether treatment with amantadine, metformin or zonisamide can help eliminate weight gain associated with olanzapine and not interfere with the positive effects of olanzapine on functioning of people with schizophrenia and other diseases
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline to Endpoint in Weight |
2.76; 2.40; 0.65 | 0.065 |
| SECONDARY Mean Change From Baseline to Endpoint in Fasting Triglycerides |
1.58; 1.61; 1.68; 0.33; 0.35; 0.06 | 0.498 |
| SECONDARY Mean Change From Baseline to Endpoint in Fasting Total Cholesterol |
5.01; 5.03; 4.91; 0.36; 0.01; -0.08 | 0.173 |
| SECONDARY Mean Change From Baseline to Endpoint in Fasting High Density Lipoprotein (HDL) Cholesterol |
1.25; 1.26; 1.22; -0.00; -0.11; -0.08 | 0.017 sig |
| SECONDARY Mean Change From Baseline to Endpoint in Fasting Low Density Lipoprotein (LDL) Cholesterol |
3.02; 3.06; 2.91; 0.16; -0.04; -0.02 | 0.152 |
| SECONDARY Mean Change From Baseline to Endpoint in Fasting Glucose |
5.32; 5.25; 5.28; 0.26; 0.10; 0.01 | 0.499 |
| SECONDARY Mean Change From Baseline to Endpoint in Hemoglobin A1c |
5.51; 5.48; 5.53; 0.09; 0.10; -0.03 | 0.278 |
| SECONDARY Change From Baseline to Endpoint in Brief Psychiatric Rating Scale (BPRS) Total Score |
48.24; 45.90; 47.00; -13.89; -9.90; -9.72 | 0.122 |
| SECONDARY Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score |
12.76; 14.22; 15.40; -6.39; -4.12; -4.36 | 0.020 sig |
| SECONDARY Change From Baseline to Endpoint in Clinical Global Impression - Severity Scale (CGI-S) |
4.06; 4.03; 4.00; -0.98; -0.72; -0.79 | 0.474 |
| SECONDARY Correlations Between Weight Changes and Changes in Eating Inventory (EI) and Food Craving Inventory (FCI) at 2 Weeks and 22 Weeks |
-0.034; 0.285; -0.273; -0.038; -0.150; 0.148 | — |
Eligibility Criteria
Inclusion Criteria
- You must have been diagnosed with schizophrenia or schizoaffective disorder
- You must be able to visit the doctor's office once every two weeks for three months, then once every four weeks for the next three months with a possible bi-weekly visit during the fifth month
- If you are currently taking a medication for schizophrenia or schizoaffective disorder, you have been taking it for at least 30 days without any changes
- If you are a female, you must have a negative pregnancy test and be using an effective method of contraception
Exclusion Criteria
- You have a diagnosis of bipolar I disorder, diabetes, very high triglyceride level (fasting triglycerides greater than or equal to 500 mg/dL), recent heart attack, stroke, uncontrolled seizures, serious infection, unstable heart disease (such as ischemic heart disease or congestive heart failure), an uncorrected narrow angle glaucoma or human immunodeficiency virus (HIV)
- You have diseases of the intestinal tract, lungs, liver, kidney, nervous or endocrine systems, or blood
- You have a diagnosis of an eating disorder
- You have a history of Parkinson's Disease or any related disorders
- You are allergic to sulfa drugs or any of the medications involved in this study
Data sourced from ClinicalTrials.gov (NCT00401973). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.